Combinations of mTORC1 inhibitor RAD001 with gemcitabine and paclitaxel for treating non-Hodgkin lymphoma |
| |
| Authors: | Chun-Te Chiang Pei-Yen Yeh Ming Gao Chun-Wei Chen Ling-Chun Yeh Wen-Chi Feng Sung-Hsin Kuo Chih-Hung Hsu Yen-Shen Lu Ann-Lii Cheng |
| |
| Affiliation: | 1. Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan;2. Department of Internal Medicine, National Taiwan University College of Medicine, Taiwan;3. Cancer Research Center and National Center of Excellence for Clinical Trial and Research, National Taiwan University Hospital, Taipei, Taiwan |
| |
| Abstract: | Single-agent mammalian target of rapamycin complex 1 (mTORC1) inhibitors have recently been reported as effective salvage treatment in non-Hodgkin lymphoma (NHL). The combined effect of mTORC1 inhibitor, RAD001, with chemotherapeutic agents used for relapsed or refractory NHL was examined. Synergistic interactions were observed for RAD001 plus gemcitabine or paclitaxel in six NHL cell lines; enhanced gemcitabine- and paclitaxel-induced caspase-dependent apoptosis associated with down-regulation of mTOR signaling was detected. Synergistic interactions were also observed with RAD001 plus gemcitabine and paclitaxel. In conclusion, synergistic cytotoxicity was observed with RAD001 plus gemcitabine and paclitaxel in NHL cells. Combination therapy with these three drugs should be examined in patients with refractory or relapsed NHL. |
| |
| Keywords: | RAD001 Gemcitabine Paclitaxel Non-Hodgkin lymphoma mTOR |
| 本文献已被 ScienceDirect 等数据库收录！ |
